Today's SA stock is ,, ZOLL as a hold ,,
There are only 4 defibrillator manufacturers ,, and 3 of them got bought out by 3M ,, HP and Siemens,,
ZOLL is only remaining ,, with more than 50% owned by institutions,,
MARQ got bought at 48 ,, from 22 bucks,,, the hype on defibs are all over the place.. as Tom Brakaw did a piece on it on Wednesday .
Seattle will place defibs in each police patrol car ,, and every airliones wil now carry one in each airplanes,, every train,,bus..shopping mall,,schools ,,churches,, think of it ... in every city and county ,,
zoll.com
ZOLL Medical Corporation designs, manufactures and markets an integrated line of proprietary noninvasive cardiac resuscitation devices, disposable electrodes, mobile ECG systems, and EMS data management solutions. Used by health care professionals to provide both types of cardiac resuscitation -- pacing and defibrillation -- these products are essential in the emergency treatment of cardiac arrest victims both inside and outside the hospital.
It is ZOLL Medical's goal to signifigantly increase this percentage, because in cardiac arrest, the need for early defibrillation is clear and deserves the highest priority.
How does ZOll plan to meet this goal? The most efficient way is to put quality defibrillators in the hands of :
Public/First Responders
Paramedics and EMT's
ALS and BLS Hospital Staff
It's a fact: According to the American Heart Association, it is estimated that only 30% of emergency responders and even fewer hospitals are sufficiently equipped to meet the AHA recommendations.
ZOLL MEDICAL CORPORATION ADOPTS SHAREHOLDER RIGHTS PLAN
-- Declares Dividend Distribution of Preferred Stock Purchase --
BURLINGTON, MA, June 9, 1998 -- ZOLL Medical Corporation (Nasdaq: ZOLL) announced today that on June 8, 1998, its Board of Directors adopted a Shareholder Rights Plan. Rolf Stutz, Chairman and Chief Executive Officer of ZOLL, stated "The Plan is designed to enhance the Board's ability to protect shareholder interests and to ensure that shareholders receive fair treatment in the event any coercive takeover attempt of ZOLL is made in the future. The Plan is intended to provide the Board with sufficient time to consider any and all alternatives to such an action. The Plan is not being adopted in response to any takeover attempt and the Company is not aware of any such attempt."
In connection with the adoption of the Shareholder Rights Plan, the Board of Directors declared a dividend distribution of one preferred stock purchase right for each outstanding share of common stock to stockholders of record as of the close of business on June 9, 1998. Initially, these rights will not be exercisable and will trade with the shares of ZOLL's common stock. Under the Shareholder Rights Plan, the rights generally become exercisable if a person becomes an "acquiring person" by acquiring 15% or more of the common stock of ZOLL, if a person who owns 10% or more of the common stock of ZOLL is determined to be an "adverse person" by the Board of Directors, or if a person commences a tender offer that would result in that person owning 15% or more of the common stock of ZOLL. Under the Shareholder Rights Plan, a shareholder of ZOLL who beneficially owns 15% or more of the Company's common stock as of 12:01 AM, Boston time, on June 8, 1998 generally will be deemed an "acquiring person" if such shareholder acquires additional shares of the Company's common stock. In the event that a person becomes an "acquiring person" or is declared an "adverse person" by the Board, each holder of a right (other than the acquiring person or the adverse person) would be entitled to acquire such number of shares of preferred stock which are equivalent to ZOLL common stock having a value of twice the then-current exercise price of the right. If ZOLL is acquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company's common stock having a value of twice the exercise price of the right. Additional details concerning the terms of the Shareholder Rights Plan will be outlined in a letter which will be mailed to shareholders following the June 9, 1998 record date.
ZOLL Medical Corporation designs manufactures and markets an integrated line of proprietary non-invasive resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation --pacing and defibrillation--these products are essential in the emergency treatment of cardiac arrest victims both inside and outside the hospital. ZOLL also designs and markets software, which automates collection and management of both clinical and non-clinical data for emergency medical service providers.
ZOLL MEDICAL CORP. ANNOUNCES CHANGES TO MANAGEMENT TEAM
BURLINGTON, MA, September 25, 1998 – ZOLL Medical Corporation (Nasdaq: ZOLL) today announced two changes to its management team. William Knight, age 49, Chief Financial Officer, has resigned to accept a position with another company. In the interim, Richard Packer, age 41, President, will assume Mr. Knight's responsibilities until a search for a successor is completed. Mr. Packer had been Chief Financial Officer of ZOLL Medical until June of 1996 when he was promoted to his current position.
In addition, Steven K. Flora, age 47, was appointed to the new position of VP of North American Sales. Mr. Flora will be responsible for leading the recently realigned sales force. Most recently, he served as Vice President of North American Sales for Marquette Medical Systems, Inc. (Nasdaq: MARQ....$47.00 dolllar company...), a leading manufacturer of medical electronics equipment and systems for diagnostic cardiology, patient monitoring and integration of clinical information. As such, he was responsible for establishing Marquette Medical Systems as a market leader and managed a sales force of 300 representatives.
Mr. Packer, commented, "On behalf of our Company and our Board of Directors, we thank Bill for his many contributions to ZOLL Medical. We wish him every success in his future endeavors."
Mr. Packer continued, "In addition, we are very pleased to welcome Steve to our team. His extensive sales experience, outstanding record and knowledge of the medical device industry will be of benefit to ZOLL Medical."
ZOLL MEDICAL CORP. SIGNS AGREEMENT WITH CHICAGO FIRE DEPARTMENT
--The Chicago Fire Department To Go Paperless-- WESTECH's Largest Order To Date, Totaling $1.25 Million --
BURLINGTON, MA, August 21, 1998 – ZOLL Medical Corporation (Nasdaq: ZOLL) today announced an agreement with The Chicago Fire Department to supply its proprietary WESTECH Data Management Software, a paperless, or electronic patient call reporting system, at each of the city's EMS stations. This agreement, valued at $1.25 million, will enable the Chicago Fire Department's ambulances to migrate from its current paper call report system to an advanced pen-computer application by using the WESTECH system.
The Chicago Fire Department's EMS Services is one of the largest municipal providers of advanced life support in the United States, operating 59 ALS vehicles with over 200,000 calls per year. ZOLL will provide the Chicago Fire Department with WESTECH software, services and rugged HUSKY PX5 computers to replace its current paper call report system with an advanced pen-computer. Commissioner Cortez Trotter, head of EMS Services, commented, "This paperless system is expected to pay for itself in just over one year as a result of faster and more effective billing." The first part of the order is expected to ship during the current quarter, with the remaining to be shipped over the balance of fiscal 1999.
ZOLL's WESTECH Mobile Solution's EMS System incorporates proprietary software programs for the electronic collection of all EMS and patient information on pen-based computers which interface with other software applications used by customers for billing, dispatching, and archiving. This system includes standardized patient care documentation, quality assurance reporting, billing, direct links to regional and state EMS regulatory offices and comprehensive management tools which improve productivity and efficiency.
ZOLL ANNOUNCES LAUNCH OF NEW HIGH PERFORMANCE "MSERIES" PRODUCT LINE
BURLINGTON, MA, June 17, 1998 -- ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices, announced today the launch of its new line of emergency resuscitation units, the "MSeries". These products, which combine monitoring, defibrillation and ZOLL's patented external pacing technology, are scheduled to ship in the Company's fourth quarter.
Mr. Richard A. Packer, President and Chief Operating Officer of ZOLL Medical Corp., said, "We expect an impressive response to the "MSeries". This highly-advanced product, integrates virtually every technology important in resuscitation, with capabilities covering the entire market for emergency resuscitation products from the professional first responder to advanced multiple parameter transport and critical care."
According to ZOLL, the "MSeries" is the most advanced defibrillator in the $450M worldwide defibrillator market. The product weighs 11 lbs., approximately one-third the size and one-half the weight of any competitor's full feature defibrillator in the industry. Due to the state of the art Field Emission Display (F. E. D.) technology, the "MSeries" provides a bright, high contrast display of cardiac rhythm, a critical capability for any emergency unit. In addition, this product is built on a technology platform that will be expanded in the future to allow the addition of significant new features such as physiological monitoring capability.
Mr. Packer continued, "The "MSeries" clearly establishes our technical leadership. Reactions at recent trade shows in the U.S. and Europe indicate that the product is on the mark for customers looking for a smaller, lighter and faster product, that is both all inclusive and easy to operate."
In April the Company announced the realignment if its North American sales organization, which resulted in two distinct sales forces, one focused on pre-hospital sales, and the other, the hospital market. These sales teams were further strengthened by adding ten new sales representatives. This change is designed to significantly improve ZOLL's competitiveness in each market.
Mr. Packer concluded, "With the focusing of the North American sales teams and release of a new product platform, we feel ZOLL is positioned for higher revenue growth. In addition to what we believe will be compelling market appeal, this platform technology, can allow us to further improve our manufacturing efficiencies and cost structure. Taken together, we expect the "MSeries" to contribute to significantly improved operating results."
ZOLL MEDICAL CORPORATION APPOINTS DANIEL M. MULVENA TO ITS BOARD OF DIRECTORS
Burlington, MA, May 22, 1998 -- ZOLL Medical Corporation (Nasdaq: ZOLL), a specialized manufacturer of non-invasive cardiac resuscitation devices, today announced the appointment of Daniel M. Mulvena, age 49, to its Board of Directors. Mr. Mulvena replaces C. William Zadel who has retired from the Board. With this replacement, ZOLL has eight members on its Board of Directors.
Mr. Mulvena has been the owner of Commodore Associates, a consulting firm working with various medical device companies, since April 1995. Prior to that, Mr. Mulvena worked as a Group Vice President with Boston Scientific Corporation (NYSE: BSX), a worldwide leader in the development, manufacturing and marketing of minimally invasive devices in cardiology, urology, gastroentology and radiology. Mr. Mulvena also held the position of Chairman, President and Chief Executive Officer with Lithox Systems, Inc. a developer, manufacturer and marketer for the non-surgical treatment of gallstones, where he joined in 1989. From 1972 to 1989, Mr. Mulvena held various executive positions, including President of Bard Implants and Bard Cardiosurgery, divisions of C.R. Bard, Inc. (NYSE: BCR), a leading health care company. Mr. Mulvena also serves on the Board of Directors of Thoratech Laboratories and Echo-Cath, Inc. (Nasdaq: ECHTA).
Rolf S. Stutz, Chairman and Chief Executive Officer, said, "Dan's extensive expertise with medical device companies will be of great value to ZOLL. His knowledge in the areas of technology, manufacturing, sales and marketing is an asset to our strategic growth initiatives. We are pleased to welcome Dan, who is well-respected in both the financial and health care community, to ZOLL's Board of Directors."
Field Emission Displays Move Into Medical Device Market
In a development that marks the entry of field emission display (FED) into the medical device industry, Zoll Medical Corp. (Burlington, MA) has incorporated an FED produced by PixTech Inc. (Santa Clara, CA) into its portable defibrillator. Zoll has ordered 50,000 displays from PixTech for use in its Mseries product. This is the first time that an FED has been used in a medical device.
PixTech operates a flat-panel display pilot manufacturing facility in Montpellier, France and an R&D facility and sales office in Santa Clara, Calif. PixTech is currently developing high- volume manufacturing capabilities for its FEDs in Taiwan, under a contract manufacturing arrangement with Unipac, a Taiwanese AM-LCD manufacturer.
|
